IP Library Granted Patent US 7,857,773
Granted Patent B2
US 7,857,773 · App. 11/414,080 · Granted Dec 28, 2010

Apparatus and methods for the destruction of adipose tissue

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,857,773
App. No.
11/414,080
Granted
Dec 28, 2010
Kind
B2
Abstract

Methods and apparatus are described for modifying unwanted tissue for cosmetic reasons. The methods provide a non-invasive manner to perform body contouring by destroying adipose tissue while simultaneously causing collagen contraction in a single procedure so that as destroyed tissue is removed from a treatment volume, the volume shrinks gradually to maintain the skin tone of the treatment area.

Claims (25)

1. A method of modifying adipose tissue in a patient using high intensity focused ultrasound, the method comprising the steps of:

determining a volume of adipose tissue to be treated;

identifying a corresponding surface area of skin over said volume of adipose tissue;

marking the patient's skin to create a plurality of guide markers at a predetermined spacing on the patient's skin within the surface area;

moving a HIFU therapy transducer successively from guide marker to guide marker on said surface area of skin; and

applying therapeutic ultrasound energy into said volume of adipose tissue at a power and for a time at each of said guide markers, wherein the power and time of applying said energy and the spacing of said guide markers are selected such that a plurality of necrosed tissue cells and denatured collagen fibrils are produced within a plurality of adjacent treatment cells covering substantially all of the treatment volume.

2. The method as described in claim 1 , wherein moving the HIFU therapy transducer is performed in a raster scan pattern.

3. The method as described in claim 1 , wherein the plurality of cells form a contiguous lesion field.

4. The method as described in claim 1 , wherein the moving the transducer is done in a continuous motion.

5. The method as described in claim 1 , wherein the moving the transducer is done in a discontinuous motion.

6. The method as described in claim 1 wherein moving the HIFU transducer is done while applying therapeutic ultrasound energy.

7. The method as described in claim 1 , wherein moving the HIFU transducer is done when the transducer is not applying ultrasound energy.

8. The method as described in claim 1 , wherein the applying of therapeutic ultrasound energy raises the temperature of the focal zone to at least 46° C.

9. The method as described in claim 1 , wherein the applying of therapeutic ultrasound energy raises the temperature of the adipose tissue to at least 56° C. for at least one second.

10. The method of claim 1 , wherein the thermal energy may be measured as an energy flux (EF) and determined by the relationship:

[(p)×(l/v)×(dc)×(nl)]/(sa)

wherein

p=power,

l=line length,

v=velocity,

dc=duty cycle,

nl=number of lines

and

sa=scanned area.

11. The method of claim 10 , wherein the energy flux is between 35 J/cm 2 and 460 J/cm 2 .

Assignments (19)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 9, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 063942/0001 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
MERGER Recorded May 17, 2021
From: LIPOSONIX, INC.
To: SOLTA MEDICAL, INC.
Reel/Frame 056257/0362 →
CHANGE OF NAME Recorded May 12, 2021
From: MEDICIS TECHNOLOGIES CORPORATION
To: LIPOSONIX, INC.
Reel/Frame 056228/0375 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: SILICON VALLEY BANK
To: LIPOSONIX, INC.
Reel/Frame 032126/0531 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: LIPOSONIX, INC.
Reel/Frame 032126/0370 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Nov 19, 2013
From: LIPOSONIX, INC.
To: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031674/0454 →
SECURITY INTEREST - MEZZANINE LOAN Recorded Apr 18, 2013
From: LIPOSONIX, INC.
To: SILICON VALLEY BANK
Reel/Frame 030249/0268 →
SECURITY AGREEMENT Recorded Apr 3, 2013
From: LIPOSONIX, INC.
To: SILICON VALLEY BANK
Reel/Frame 030147/0642 →
CHANGE OF NAME Recorded Apr 24, 2009
From: LIPOSONIX, INC.
To: MEDICIS TECHNOLOGIES CORPORATION
Reel/Frame 022597/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2006
From: DESILETS, CHARLES S.; POLLOCK, CAMERON
To: LIPOSONIX, INC.
Reel/Frame 018546/0477 →